Interactive Financial Charts Not Available

Bristol-Myers Squibb (BMY) | Financial Analysis & Statements

Bristol-Myers Squibb Company | Large-cap | Healthcare

$45.95

1.30%

| Bristol-Myers Squibb Stock Comparison:

Bristol-Myers Squibb vs Eli Lilly and Bristol-Myers Squibb vs Johnson & Johnson Bristol-Myers Squibb vs Amgen Bristol-Myers Squibb vs Gilead Sciences Bristol-Myers Squibb vs Pfizer Bristol-Myers Squibb vs S&P 500 | Market

TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 12.3B

Gross Profit 8.9B 72.52%

Operating Income 3.8B 30.76%

Net Income 1.3B 10.70%

Balance Sheet Metrics

Total Assets 92.4B

Total Liabilities 75.0B

Shareholders Equity 17.4B

Debt to Equity 4.30

Cash Flow Metrics

Operating Cash Flow 2.1B

Free Cash Flow 1.7B

Revenue & Profitability Trend

Interactive Financial Charts Not Available

This page uses interactive financial charts and dynamic data visualization tools that require JavaScript. For detailed financial analysis:

Available Financial Data:

Income statements (annual and quarterly)
Balance sheets with asset and liability details
Cash flow statements and free cash flow analysis
Key financial ratios and performance metrics
Peer comparison and industry benchmarking

All financial data is displayed in accessible table format below. Use the table headers and structure to analyze trends and compare metrics across different periods.

Bristol-Myers Squibb Income Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Revenue i	48.3B	45.0B	46.2B	46.4B	42.5B
Cost of Goods Sold i	14.0B	10.7B	10.1B	9.9B	11.8B
Gross Profit i	34.3B	34.3B	36.0B	36.4B	30.7B
Gross Margin % i	71.1%	76.2%	78.0%	78.6%	72.3%
Operating Expenses
Research & Development i	11.2B	9.3B	9.5B	10.2B	11.1B
Selling, General & Administrative i	8.4B	7.8B	7.8B	7.7B	7.7B
Other Operating Expenses i	-	-	-	-	530.0M
Total Operating Expenses i	19.6B	17.1B	17.3B	17.9B	19.3B
Operating Income i	5.9B	8.2B	9.1B	8.5B	2.2B
Operating Margin % i	12.2%	18.2%	19.7%	18.4%	5.1%
Non-Operating Items
Interest Income i	-	-	-	-	-
Interest Expense i	1.9B	1.2B	1.2B	1.3B	1.4B
Other Non-Operating Income	-12.3B	1.4B	-159.0M	895.0M	-7.6B
Pre-tax Income i	-8.4B	8.4B	7.7B	8.1B	-6.9B
Income Tax i	554.0M	400.0M	1.4B	1.1B	2.1B
Effective Tax Rate % i	0.0%	4.7%	17.7%	13.4%	0.0%
Net Income i	-8.9B	8.0B	6.3B	7.0B	-9.0B
Net Margin % i	-18.5%	17.9%	13.7%	15.1%	-21.2%
Key Metrics
EBITDA i	17.2B	19.3B	20.6B	20.4B	14.3B
EPS (Basic) i	$-4.41	$3.88	$2.97	$3.15	$-3.99
EPS (Diluted) i	$-4.41	$3.86	$2.95	$3.12	$-3.99
Basic Shares Outstanding i	2027000000	2069000000	2130000000	2221000000	2258000000
Diluted Shares Outstanding i	2027000000	2069000000	2130000000	2221000000	2258000000

Income Statement Trend

Bristol-Myers Squibb Balance Sheet From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Assets
Current Assets
Cash & Equivalents i	10.3B	11.5B	9.1B	14.0B	14.5B
Short-term Investments i	513.0M	816.0M	130.0M	3.2B	1.9B
Accounts Receivable i	9.0B	8.9B	8.2B	8.0B	7.2B
Inventory i	2.6B	2.7B	2.3B	2.1B	2.1B
Other Current Assets	1.9B	1.5B	1.6B	1.3B	1.0B
Total Current Assets i	29.8B	31.8B	27.3B	33.3B	30.2B
Non-Current Assets
Property, Plant & Equipment i	1.2B	1.4B	1.2B	919.0M	859.0M
Goodwill i	67.1B	69.8B	78.7B	83.8B	94.5B
Intangible Assets i	23.6B	27.5B	36.4B	42.8B	53.4B
Long-term Investments	-	-	-	-	-
Other Non-Current Assets	6.4B	4.4B	2.1B	2.8B	2.8B
Total Non-Current Assets i	62.8B	63.4B	69.5B	76.1B	88.3B
Total Assets i	92.6B	95.2B	96.8B	109.3B	118.5B
Liabilities
Current Liabilities
Accounts Payable i	3.6B	3.3B	3.0B	2.9B	2.7B
Short-term Debt i	2.2B	3.3B	4.4B	5.1B	2.5B
Current Portion of Long-term Debt	-	-	-	-	-
Other Current Liabilities	12.9B	11.5B	10.6B	10.1B	10.2B
Total Current Liabilities i	23.8B	22.3B	21.9B	21.9B	19.1B
Non-Current Liabilities
Long-term Debt i	49.0B	38.2B	36.3B	40.5B	49.2B
Deferred Tax Liabilities i	369.0M	338.0M	2.2B	4.5B	5.4B
Other Non-Current Liabilities	522.0M	396.0M	303.0M	218.0M	326.0M
Total Non-Current Liabilities i	52.4B	43.4B	43.8B	51.4B	61.5B
Total Liabilities i	76.2B	65.7B	65.7B	73.3B	80.6B
Equity
Common Stock i	292.0M	292.0M	292.0M	292.0M	292.0M
Retained Earnings i	14.9B	28.8B	25.5B	23.8B	21.3B
Treasury Stock i	43.7B	43.8B	38.6B	31.3B	26.2B
Other Equity	-	-	-	-	-
Total Shareholders Equity i	16.4B	29.5B	31.1B	36.0B	37.9B
Key Metrics
Total Debt i	51.2B	41.5B	40.7B	45.6B	51.7B
Working Capital i	6.0B	9.5B	5.4B	11.4B	11.1B

Balance Sheet Composition

Bristol-Myers Squibb Cash Flow Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Operating Activities
Net Income i	-8.9B	8.0B	6.3B	7.0B	-9.0B
Depreciation & Amortization i	9.6B	9.8B	10.3B	10.7B	10.4B
Stock-Based Compensation i	507.0M	518.0M	457.0M	583.0M	779.0M
Working Capital Changes i	2.1B	-1.3B	-806.0M	-198.0M	3.3B
Operating Cash Flow i	14.6B	14.9B	14.6B	17.5B	15.9B
Investing Activities
Capital Expenditures i	-	-	-	-	-
Acquisitions i	-20.7B	-260.0M	-3.0B	-862.0M	-12.3B
Investment Purchases i	-769.0M	-1.8B	-3.6B	-5.5B	-4.2B
Investment Sales i	1.4B	948.0M	6.6B	6.8B	6.4B
Investing Cash Flow i	-20.1B	-1.1B	56.0M	435.0M	-10.1B
Financing Activities
Share Repurchases i	0	-5.2B	-8.0B	-6.3B	-1.5B
Dividends Paid i	-4.9B	-4.7B	-4.6B	-4.4B	-4.1B
Debt Issuance i	12.9B	4.5B	5.9B	0	6.9B
Debt Repayment i	-5.9B	-3.9B	-11.4B	-6.0B	-2.8B
Financing Cash Flow i	2.2B	-9.4B	-17.9B	-16.2B	-1.2B
Free Cash Flow i	13.9B	12.7B	11.9B	15.2B	13.3B
Net Change in Cash i	-3.2B	4.4B	-3.3B	1.7B	4.7B

Cash Flow Trend

Bristol-Myers Squibb Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 18.00

Forward P/E 6.38

Price to Book 5.23

Price to Sales 1.91

PEG Ratio 6.38

Profitability Ratios

Profit Margin 10.58%

Operating Margin 33.66%

Return on Equity 29.32%

Return on Assets 8.34%

Financial Health

Current Ratio 1.21

Debt to Equity 291.55

Beta 0.37

Per Share Data

EPS (TTM) $2.49

Book Value per Share $8.57

Revenue per Share $23.49

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
bmy	91.2B	18.00	5.23	29.32%	10.58%	291.55
Eli Lilly and	687.2B	62.24	46.02	77.28%	22.67%	243.61
Johnson & Johnson	411.9B	18.31	5.25	30.21%	25.00%	64.69
Amgen	153.3B	23.26	20.63	99.14%	18.96%	756.65
Gilead Sciences	142.4B	24.06	7.44	32.65%	20.76%	130.79
Pfizer	133.8B	17.05	1.48	8.62%	12.62%	68.84

Financial data is updated regularly. All figures are in the company's reporting currency.